IL235874A0 - Treatment of ocular inflammatory diseases by laquinimod - Google Patents

Treatment of ocular inflammatory diseases by laquinimod

Info

Publication number
IL235874A0
IL235874A0 IL235874A IL23587414A IL235874A0 IL 235874 A0 IL235874 A0 IL 235874A0 IL 235874 A IL235874 A IL 235874A IL 23587414 A IL23587414 A IL 23587414A IL 235874 A0 IL235874 A0 IL 235874A0
Authority
IL
Israel
Prior art keywords
laquinimod
treatment
inflammatory diseases
ocular inflammatory
ocular
Prior art date
Application number
IL235874A
Other languages
English (en)
Hebrew (he)
Original Assignee
Teva Pharma
Tarcic Nora
Kaye Joel
Hallak Hussein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Tarcic Nora, Kaye Joel, Hallak Hussein filed Critical Teva Pharma
Publication of IL235874A0 publication Critical patent/IL235874A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL235874A 2012-06-05 2014-11-24 Treatment of ocular inflammatory diseases by laquinimod IL235874A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261655526P 2012-06-05 2012-06-05
PCT/US2013/044058 WO2013184650A2 (en) 2012-06-05 2013-06-04 Treatment of ocular inflammatory diseases using laquinimod

Publications (1)

Publication Number Publication Date
IL235874A0 true IL235874A0 (en) 2015-01-29

Family

ID=49671002

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235874A IL235874A0 (en) 2012-06-05 2014-11-24 Treatment of ocular inflammatory diseases by laquinimod

Country Status (10)

Country Link
US (6) US20130324574A1 (enExample)
EP (1) EP2854767A4 (enExample)
JP (2) JP2015523986A (enExample)
AR (1) AR092842A1 (enExample)
CA (1) CA2874767A1 (enExample)
IL (1) IL235874A0 (enExample)
RU (1) RU2014151992A (enExample)
TW (1) TW201400117A (enExample)
UY (1) UY34843A (enExample)
WO (1) WO2013184650A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2015073697A1 (en) * 2013-11-15 2015-05-21 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
AU2022248724A1 (en) * 2021-04-01 2023-11-02 Active Biotech Ab Laquinimod formulation for ocular use

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20050074451A1 (en) 2003-06-25 2005-04-07 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
AU2005231467A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
CA2565545A1 (en) 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
CA2579038A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
BRPI0617477A2 (pt) 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
AU2006307939B2 (en) 2005-10-26 2012-03-29 Merck Serono Sa Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
US8410115B2 (en) 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
KR20080104343A (ko) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
WO2007146331A1 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
EP1886996A1 (en) 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
CA2693697C (en) 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8354428B2 (en) 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
AU2009288108B2 (en) 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
NZ597378A (en) 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
BR112012002124A2 (pt) 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
TWI620569B (zh) * 2009-12-15 2018-04-11 遠景生物製藥股份有限公司 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
US20110217295A1 (en) 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
KR20130006640A (ko) 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
EA201290860A1 (ru) 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
WO2011112586A2 (en) 2010-03-08 2011-09-15 Cornell University Methods for diagnosing feline coronavirus infections
WO2012001647A2 (en) * 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
JP5934202B2 (ja) 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
AU2011274496B2 (en) 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2012075490A2 (en) 2010-12-03 2012-06-07 Duke University Anti-podoplanin antibodies and methods of use
PE20140872A1 (es) 2010-12-07 2014-08-09 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
SG10201606191PA (en) 2011-07-28 2016-09-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
HK1198278A1 (en) 2011-07-28 2015-03-27 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201804997A (zh) 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410243A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015004564A (es) 2012-10-12 2015-07-21 Teva Pharma Laquinimod para producir el daño talamico en la esclerosis multiple.
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода

Also Published As

Publication number Publication date
US20130324574A1 (en) 2013-12-05
AR092842A1 (es) 2015-05-06
US20170231971A1 (en) 2017-08-17
UY34843A (es) 2013-12-31
US11654140B2 (en) 2023-05-23
WO2013184650A3 (en) 2015-07-02
WO2013184650A2 (en) 2013-12-12
US20180071275A1 (en) 2018-03-15
US20170333420A1 (en) 2017-11-23
TW201400117A (zh) 2014-01-01
US20250134881A1 (en) 2025-05-01
EP2854767A4 (en) 2016-04-27
RU2014151992A (ru) 2016-07-27
JP2018024677A (ja) 2018-02-15
US20210386731A1 (en) 2021-12-16
CA2874767A1 (en) 2013-12-12
EP2854767A2 (en) 2015-04-08
JP2015523986A (ja) 2015-08-20

Similar Documents

Publication Publication Date Title
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
IL237070B (en) Treatment of vaccine-related diseases and inflammatory diseases
IL229017B (en) Oxidative retinal diseases
ZA201500561B (en) Compositions and treatment for eye diseases and disorders
EP2869833A4 (en) TREATMENT OF INFLAMMATORY SKIN DISORDERS
ZA201309557B (en) Methods of treatment for retinal diseases
GB201506561D0 (en) Treatment of amblyopia
ZA201503979B (en) Treatment of diseases involving mucin
IL234606B (en) Novel methods and composition for treatment of disease
EP2854767A4 (en) TREATMENT OF OCULAR INFLAMMATORY DISEASES BY LAQUINIMOD
ZA201507718B (en) The local treatment of inflammatory ophthalmic diseases
IL245373A0 (en) Treatment of glaucoma by laquinimod
IL239273A0 (en) A method of treating diseases
EP3046629A4 (en) Treatment of inflammatory skin disease
IL239078A0 (en) Protein for use in the treatment of eye diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HK40043513B (en) Interval therapy for the treatment of eye diseases
EP2911662A4 (en) METHOD OF TREATING A DISEASE
AU2012902874A0 (en) Treatment of inflammatory skin disorders
GB201207431D0 (en) Intravaginal treatment of gynacological conditions
HK1229221A1 (en) Treatment of glaucoma using laquinimod
GB201204645D0 (en) Treatment of disease
GB201201779D0 (en) Treatment of inflammatory disorders
GB201201778D0 (en) Treatment of inflammatory respiratory disease
AU2012905519A0 (en) Treatment of diseases involving mucin